











Antiviral Therapy in Management of Chronic Hepatitis B Virus Infection in Children: A 
Systematic Review and Meta-analysis 
Authors:  
Maureen M. Jonas, MD
1 
Maureen.Jonas@childrens.harvard.edu 
































Prokop J Larry, MLS
10
 
Page 1 of 26 Hepatology
This is the author manuscript accepted for publication and has undergone full peer review but has not been
through the copyediting, typesetting, pagination and proofreading process, which may lead to differences
between this version and the Version record. Please cite this article as doi:10.1002/hep.28278.
























Division of Gastroenterology, Hepatology and Nutrition, Boston Children’s Hospital, Boston, 
MA 
2
Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA 
3
Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, 
Alaska, USA 
4Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, NY, 
USA 
5
Department of Medicine, Tufts Medical Center, Boston, Massachusetts, USA 
6
Evidence-Based Practice Research Program, Mayo Clinic, Rochester MN, USA 
7
Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA 
8
Division of Hospital Internal Medicine, Mayo clinic, Rochester, Minnesota, USA 
9Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA 
10
Library Public Services, Mayo Clinic, Rochester, MN, USA 
Page 2 of 26
Hepatology
Hepatology














Division of Preventive, Occupational and Aerospace Medicine, Mayo Clinic, Rochester, MN, 
USA 
Keywords:  Interferon, nucleos(t)ide analogues, hepatitis B e antigen, hepatitis B surface antigen 
Corresponding author: Maureen M. Jonas, MD. Division of Gastroenterology, Hunnewell 
Ground Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115. Tel: 617-355-
5837. Email: maureen.Jonas@childrens.harvard.edu 
List of Abbreviations: Hepatitis B virus (HBV), Randomized Controlled Trials (RCTs), 
Hepatitis B e Antigen (HBeAg), Hepatitis B Surface Antigen (HBsAg), Alanine 
Aminotransferase (ALT), American Association for the Study of Liver Diseases (AASLD), 
Interferon (IFN). 
Financial Support: This study was supported by a contract from the American Association for 
the Study of Liver Diseases (AASLD) to M Murad (Mayo Clinic). 
Conflict of Interest:  
Maureen M. Jonas has received research grants from Bristol Myers Squibb, Roche and Gilead, 
and serves on a Data Safety Monitoring Board for Gilead.  
Anna S. Lok has received research grants from Bristol-Myers Squibb and Gilead and has served 
on advisory panels for Gilead, GlaxoSmithKline and Merck 
Robert S. Brown has received research grants from Gilead and has served as a consultant for 
Gilead.  
B McMahon, J Wong, A Ahmed, W Farah, M Mouchli, S Singh, P Larry, M Murad, and K 
Mohammed do not have any disclosures.   
Page 3 of 26
Hepatology
Hepatology














Introduction: Most individuals with chronic hepatitis B virus (HBV) infection acquired the 
infection around the time of birth or during early childhood. We aimed to synthesize evidence 
regarding the effectiveness of antiviral therapy in the management of chronic HBV infection in 
children. Methods: We conducted a comprehensive search of multiple databases from 1988 to 
December 2nd, 2014 for studies that enrolled children (< 18 years) with chronic HBV infection 
treated with antiviral therapy.  We included observational studies and randomized controlled 
trials (RCTs). Two independent reviewers selected studies and extracted data. Results: In the 14 
included studies, 2 cohort studies showed no significant reduction in the already low risk of 
hepatocellular carcinoma or cirrhosis, and 12 RCTs reported intermediate outcomes. In RCTs 
with post-treatment follow up < 12 months, antiviral therapy compared to placebo improved 
ALT normalization (RR 2.3 (95% CI, 1.7 - 3.2), hepatitis B e antigen (HBeAg) clearance/loss 
(RR 2.1 (95% CI, 1.5 - 3.1), HBV DNA suppression (RR 2.9 (95% CI, 1.8 - 4.6), HBeAg 
seroconversion (RR 2.1 (95% CI, 1.4 - 3.3) and  hepatitis B surface antigen (HBsAg) clearance 
(RR 5.8 (95% CI, 1.1 - 31.5). In RCTs with post-treatment follow up ≥ 12 months, antiviral 
therapy improved cumulative HBeAg clearance/loss (RR 1.9 (95% CI, 1.7 - 3.1), HBeAg 
seroconversion (RR 2.1 (95% CI, 1.3 - 3.5), ALT normalization (RR 1.4 (95% CI, 1.1 – 1.7) and 
HBV DNA suppression (RR 1.4 (95% CI, 1.1 – 1.8), but not HBsAg clearance or HBsAg 
seroconversion. Conclusion: In children with chronic HBV infection, antivirals compared to no 
antiviral therapy improve HBV DNA suppression and frequency of ALT normalization and 
HBeAg seroconversion. 
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Worldwide, most individuals with chronic hepatitis B virus (HBV) infection acquired their 
infections around the time of birth or during early childhood because the risk of chronic infection 
is 90% when infection occurs in infancy, 30% when occurring during the first 5-years of life and 
decreases to <5% when infection occurs in immunocompetent older children and adults (1). In 
countries where HBV is endemic, perinatal transmission remains the most important mode of 
infection because of the high prevalence of hepatitis B e antigen (HBeAg) in pregnant women. 
Perinatal transmission also occurs in non-endemic countries, including the United States, mostly 
in children of HBV-infected mothers who did not receive appropriate screening during 
pregnancy or HBV immunoprophylaxis at birth. 
The natural history of chronic HBV infection in children varies, depending upon age at infection, 
mode of acquisition, and ethnicity. When HBV infection is acquired perinatally or horizontally 
during the first few years of life, children from HBV endemic countries usually become HBeAg-
positive with high levels of viral replication (2). Spontaneous HBeAg seroconversion rates vary 
by age and are less than 2% per year in children younger than three years of age, 4 to 5% after 
age three, and then rise during puberty.  In contrast, children from non-endemic countries are less 
likely to have acquired the infection perinatally and frequently undergo HBeAg seroconversion 
during the first two to three decades of life (3). 
Cirrhosis is an infrequent complication of HBV infection during childhood. In one of the largest 
studies, involving 292 consecutive children with a mean age of 4.0±3.3 years who were hepatitis 
B surface antigen (HBsAg) positive and who had elevated serum alanine aminotransferase 
(ALT) levels (4), 10 (3%) had cirrhosis at enrollment, but no child developed cirrhosis during 
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follow-up of 1-10 years. The risk of hepatocellular carcinoma (HCC) is related to the duration of 
infection, the degree of liver injury, and the replicative state of the virus (HBV DNA levels).  
Hepatocellular carcinoma in children with chronic HBV infection has been described in both 
Asian and Western populations (5-9). Importantly, HCC may occur even in children who have 
undergone HBeAg seroconversion at a young age, indicating that risk for developing HCC 
persists even following reduced viral replication (10). 
Management of children with chronic HBV infection involves education of the children and their 
parents on measures to prevent transmission of infection, regular follow-up to monitor viral 
replication and liver injury, and antiviral therapy and HCC surveillance in some cases(11). Few 
large trials of antiviral therapy in children exist to guide treatment decisions. In the United 
States, interferon (IFN)-alpha is approved for children beginning at 1 year of age, and 
lamivudine and entecavir are approved for use in children 2 years and older. Adefovir and 
tenofovir are approved for use in those 12 years of age and older.  IFN, lamivudine and adefovir 
are no longer first line therapy in adults, since much better agents are available, so they are less 
than ideal for children.  Randomized Phase III trials of entecavir, peginterferon-alpha2a and 
tenofovir in children with chronic HBV are underway. We conducted this systematic review and 
meta-analysis to synthesize existing evidence about effectiveness of antiviral therapy in the 
management of chronic HBV infection in children. 
Methods: 
This systematic review follows a predefined protocol that was developed by a guideline writing 
group from the American Association for the Study of Liver Diseases (AASLD) .The reporting 
of this systematic review adheres to the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) statements (12).  
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Eligibility criteria:  
We included studies that enrolled children (< 18 years) with chronic HBV infection treated with 
antiviral therapy. Due to the anticipated limited number of randomized controlled trials (RCTs) 
evaluating patient important (clinical) outcomes, we included observational studies that 
evaluated su h outcomes. Outcomes of interest were cirrhosis, decompensated liver disease, 
HCC, ALT normalization, HBV DNA suppression, HBeAg/ HBsAg seroconversion and HBeAg/ 
HBsAg loss. We included both English and non-English language studies. We excluded studies 
enrolling adults, patients co-infected with hepatitis C, D or HIV, patients receiving combination 
therapy, steroids, chemo/immunotherapy, liver transplant recipients and hemodialysis patients. 
Supplemental table 1 describes the detailed inclusion and exclusion criteria. 
Search strategy: 
The search strategy was designed and conducted by an experienced librarian (LJP) with input 
from the principal investigator. A comprehensive search of Medline In-Process & Other Non-
Indexed Citations, MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and 
Scopus was conducted from January 1988 to December 2nd, 2014. Controlled vocabulary 
supplemented with keywords was used to search for studies of antiviral therapy for hepatitis B in 
children. Supplemental table 2 provides the details of search strategy. We conducted a manual 
search of bibliographies of the included studies and previous systematic reviews to identify 
relevant studies. Content experts from AASLD were also queried for potential references. 
Study selections:  
Using an online reference management system (DistillerSR, Evidence Partners, Inc.), two 
reviewers independently screened titles and abstracts. Full text of the included abstracts were 
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retrieved and screened in duplicate. Disagreements were harmonized by consensus or through 
arbitration by a third reviewer. We calculated inter-rater agreement (Kappa) during the full text 
screening to observe the agreement between reviewers.  
Data Extraction:  
Data extraction was done in duplicates using a standardized, piloted form. A third reviewer 
compared the reviewers' entered data and resolved any inconsistencies by referring to the full 
text of the article. We extracted the following variables from each study: study characteristics, 
patient baseline characteristics, interventions details and outcomes of interest. 
Risk of bias assessment: 
Two reviewers independently assessed the risk of bias (i.e., systematic error) using the Cochrane 
risk of bias tool and the Newcastle-Ottawa Scale for RCTs and observational studies; 
respectively. Quality of evidence (i.e., certainty in the estimates) was evaluated using the 
Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. 
Criteria used to evaluate quality of evidence were risk of bias, indirectness (surrogate outcomes), 
imprecision (wide confidence intervals), inconsistency (heterogeneity) and publication bias (13). 
Statistical analysis: 
For dichotomized outcomes, we calculated risk ratios and 95% confidence intervals using 
binomial distribution. We then pooled the log transformed risk ratios using the DerSimonian and 
Laird (14) random-effect method with the heterogeneity estimated from the Mantel-Haenszel 
model. To measure the overall heterogeneity across the included studies, we calculated I² 
statistic, where I² >50% suggesting high heterogeneity (15). All statistical analyses were 
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conducted using STATA, version 13 (StataCorp LP, College Station, TX). We explored the 
impact of publication bias using the Egger regression asymmetry test and by constructing funnel 
plots if a sufficient number of studies (>20) per outcome was available and heterogeneity was 
low (16).   
Results: 
From the 2321 citations identified, with the primary search strategy, 14 studies that enrolled 
1425 children were finally included. Two studies evaluated the clinical (patient important) 
outcomes of death, cirrhosis and HCC, and 12 studies reported intermediate outcomes. Average 
weighted kappa (inter-rater agreement) for study selection was 0.75. Details of study selection 
and reasons for exclusion are described in Figure 1.  
1. Effect of antiviral therapy on clinical (patient-important) outcomes of cirrhosis and HCC: 
Two cohort studies (17) (18) from Europe and Japan reported on 163 HBeAg positive patients 
treated with multiple interventions including IFN-alpha with mean follow up of 15 years. 
Characteristics of the included studies are described in Table 1.  IFN treatment did not 
significantly reduce the risk of HCC (RR 0.3 (95% CI 0.01-156.2) or cirrhosis (RR 0.2 (95% CI 
0.01-100.7). 
2. Effect of antiviral therapy on intermediate outcomes (ALT normalization, HBV DNA 
suppression, HBeAg/ HBsAg seroconversion and HBeAg/ HBsAg loss): 
Among 12 RCTs reporting intermediate outcomes, 8 studies evaluated IFN-alpha (19-26) ; 1 
each evaluated lamivudine (27), tenofovir (28), adefovir (29) or entecavir (30). Most of the 
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studies (74%) had a high risk of bias due to unreported or unclear randomization methods, 
allocation concealment and blinding (Table 2). 
2.1 Any antiviral therapy vs control results: 
In the12 RCTs that compared  antiviral therapy to controls, 5 (20, 22, 23, 26, 30) reported 
outcomes for both short (< 12 months) and long (≥ 12 months) post-treatment follow up 
durations, 2 (19, 25, 31) included only longer (≥ 12 months) post-treatment follow up and 5 (21, 
24, 27-29) included only shorter (< 12 months) follow up. Two RCTs reported the short- and 
long-term outcomes separately for lamivudine (27,31)and adefovir (29, 32).   
In studies with post-treatment follow up < 12 months, meta-analysis (Figure 2) demonstrated that 
antiviral therapy compared to placebo was more effective at improving ALT normalization (8 
RCTs, RR 2.3 (95% CI, 1.7 - 3.2) I
2
=46.5%), HBeAg clearance/loss (7 RCTs, RR 2.1 (95% CI, 
1.5 - 3.1) I
2
=0%), HBV DNA suppression (9 RCTs, RR 3.3 (95% CI, 1.9 - 6.1) I
2
=63.8%), 
HBeAg seroconversion (4 RCTs, RR 2.1 (95% CI, 1.4 - 3.3) I
2
=0%) and HBsAg clearance (2 
RCT, RR 5.8 (95% CI, 1.1 - 31.5) I
2
=0%). In studies with post-treatment follow up ≥ 12 months 
(Figure 3), antiviral therapy improved ALT normalization (2 RCTs, RR 1.4 (95% CI, 1.1 – 1.7) 
I
2
=0%), HBeAg clearance/loss (5 RCTs, RR 2 (95% CI, 1.9 - 3.2) I
2
=0%), HBV DNA 
suppression (7 RCTs, RR 1.4 (95% CI, 1.1 – 1.8) I
2
=0%) and HBeAg seroconversion (3 RCTs, 
RR 2.1 (95% CI, 1.3 - 3.5) I
2
=0%). However, the short-term statistically significant difference 
did not persist after ≥ 12 months follow up for HBsAg clearance (2 RCTs, RR 3.3 (95% CI, 0.4 - 
27.8) I
2
=0%) and for HBsAg seroconversion (2 RCTs, RR 2.5 (95% CI, 0.3- 22.7) I
2
=0%). The 
quality of evidence was low to very low due to high risk of bias and indirectness. 
2.2 Specific antiviral therapy vs control results: 
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In studies (Figure 4) with post-treatment follow up < 12 months, IFN-alpha compared to no 
treatment significantly improved HBeAg clearance/loss (4 RCTs, RR 3.2, (95% CI, 1.8 - 5.7) 
I
2
=0%) and HBV DNA suppression (6 RCTs, RR 2.2(95% CI, 1.4 - 3.3) I
2
=0%) but did not 
significantly improve ALT normalization (4 RCTs, RR 1.4 (95% CI, 0.9 - 2.3) I
2
=0%), HBeAg 
seroconversion (1 RCT, RR 2.8 (95% CI, 0.8 - 9.4) or HBsAg clearance (1 RCT, RR 7.4 
(95%CI, 0.9 - 58.6). In studies ( Figure 5) with post-treatment follow up ≥ 12 months, IFN alpha 
use was associated with improved HBeAg clearance/loss (5 RCTs, RR 2.0 (95% CI, 1.9 - 3.2) 
I
2
=0%) and HBeAg seroconversion (2 RCTs, RR 3.1 (95%CI, , 1.2 - 8.1) I
2
=0%), but 
statistically significant differences were not observed for ALT normalization (1 RCTs, RR 1.4 
(95% CI, 0.6 - 1.9), HBV DNA suppression(6 RCTs, RR 1.5 (95% CI, 0.99 - 2.1) I
2
=7.6%), 
HBsAg clearance (2 RCTs, RR 3.3 (95% CI, 0.4 - 27.8) I
2
=0%) or HBsAg seroconversion (2 
RCTs, RR 2.5 (95% CI, 0.3 - 22.7) I
2
=0%). The quality of evidence was low to very low due to 
risk of bias, indirectness and imprecision. 
Lamivudine, when compared to placebo (27), was associated with significantly higher likelihood 
of ALT normalization (1 RCT, RR 4.5 (95% CI, 2.3 - 9.1), HBeAg clearance/loss (1 RCT, RR 
1.8 (95% CI, 1 - 3.1) and HBV DNA suppression (1 RCT, RR 3.9 (95% CI, 2.4 - 6.3) but not 
HBeAg seroconversion (2 RCTs, RR 1.7 (95% CI, 0.96 - 3.2) or HBsAg clearance (1 RCT, RR 
3.5 (95% CI, 0.2 - 67.1) at the end of 48 weeks treatment. The quality of evidence was moderate 
to low, due to indirectness and imprecision. 
One RCT (29, 31) compared adefovir to placebo treatment. After 48 weeks of treatment, 
adefovir was associated with a higher rate of ALT normalization (RR 2.7 (95% CI,1.6 - 4.6) and 
HBV DNA suppression (RR 11.1 (95% CI, 1.5 – 80.3) but not HBeAg seroconversion (RR 3 
(95% CI, 0.9 - 9.9). Longer follow up (192 weeks) of the same cohort with open-label adefovir 
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treatment either alone or with lamivudine showed continued viral suppression and ALT 
normalization (32). The quality of evidence was moderate to low due to indirectness and 
imprecision. 
One RCT (28) compared tenofovir to placebo treatment. After 72 weeks of treatment, tenofovir 
demonstrated significantly higher rates of ALT normalization (RR 2 (95% CI, 1.4 - 2.9)) and 
HBV DNA suppression (RR 92.4 (95% CI, 5.8-146.7)), but no statistically significant effect on 
HBeAg clearance/loss (RR 1.4 (95% CI, 0.6 - 3.4)). The quality of evidence was moderate to 
low due to indirectness and imprecision.  
In one RCT (30), entecavir compared to placebo was associated with higher ALT normalization 
(RR 2.9 (95% CI, 1.8-4.7), HBV DNA suppression (RR 14.8 (95% CI, 3.7 – 58.3) and HBeAg 
seroconversion (RR 2.4 (95% CI, 1.1 – 5.5) at 48 weeks. Longer duration of treatment (96 
weeks) resulted in persistently statistically significant HBeAg seroconversion (RR 1.8 (95% CI, 
1.0 – 3.4) but not ALT normalization (RR 1.1 (95% CI, 0.9-1.4) and HBV DNA suppression (RR 
1.2 (95% CI, 0.9 – 1.7). The quality of evidence was limited due to the use of surrogate 
outcomes. 
A detailed summary of the assessment of quality of evidence is provided in Supplemental Table 
3. 
Publication bias: We were unable to evaluate publication bias due to the small number of 
studies for each outcome.  
Discussion: 
Main findings:  
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In this systematic review evaluating the effectiveness of antiviral therapy in children, we 
identified 14 studies. The current evidence demonstrates that antiviral therapy improves the 
frequency of surrogate outcomes (ALT normalization, HBeAg loss, HBV DNA suppression, 
HBeAg seroconversion and HBsAg loss) when compared to no or placebo treatment. The 
confidence in this evidence is limited by the short duration of follow-up, certain methodological 
limitations that relate to randomization and blinding processes, and the minimal data on patient-
important outcomes such as cirrhosis and HCC. 
Strengths and limitations: Although relatively few in number, some large, randomized trials of 
antiviral agents inform clinical decision-making in pediatric HBV infection.  In general, the 
primary outcomes of these studies, including HBV DNA suppression, HBeAg loss and 
seroconversion, and ALT normalization, were used as surrogates for the clinical outcomes of 
cirrhosis, HCC and death, since the latter are quite rare during childhood. Despite this limitation, 
this is the reality of pediatric practice, and some data support the use of HBeAg seroconversion 
and viral suppression as therapeutic endpoints, particularly if these are durable.  Going forward, 
future trials of antivirals in children should evaluate long-term durability of the surrogate 
outcomes.  As for clinical outcomes; which require a very long follow up that may be 
challenging for randomized trials, we suggest the use of registries and large databases of treated 
children. Such observational studies can provide evidence on clinical outcome and can inform 
decision making if the studies had rigorous design features to protect from bias (e.g. prospective 
data entry, multivariable adjustment for prognostic factors and minimal loss to follow up). . 
Currently approved therapeutic agents have acceptable safety profiles in children and 
adolescents. IFN has a side effect profile similar to that seen in adults, and transient effects on 
body weight and growth have been observed (33), but no long-term safety issues have been 
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identified. Oral antivirals are both safe and well-tolerated, but viral resistance with lamivudine 
and adefovir develops at least as often in children as in adults (34).  Development of viral 
resistance is less common with entecavir (22), as has been the case in adults. 
Clinical and research implications: Some children with chronic HBV infection may  benefit from 
treatment, at least with respect to the surrogate outcomes of HBV DNA suppression and HBeAg 
seroconversion. The effect of treatment in preventing serious sequelae, such as cirrhosis and 
HCC, in young adult life remains unproven.  ALT levels less than 1.5 to 2 times the upper limit 
of normal (ULN) in a child who is HBeAg-positive with high HBV DNA levels (>10 million 
IU/ml) generally indicates that the child is in the immune tolerant phase of HBV infection. Such 
children are not typically candidates for treatment, because treatment with any of the currently 
available drugs has not been demonstrated to improve HBeAg seroconversion compared with no 
treatment. Children with ALT values greater than 10 times the ULN may be in the process of 
spontaneous HBeAg seroconversion and should be observed for several months before treatment 
is begun. Therapeutic choices for children with chronic hepatitis B have been limited but 
expanding, since entecavir has recently been shown to be safe and effective in this population, 
and data regarding peginterferon and tenofovir use in children are expected soon.  Therefore, the 
choice of whether to treat now or to monitor depends on patient-specific characteristics that 
predict the efficacy of treatment, including persistently abnormal ALT levels or active disease on 
liver biopsy, as well as considerations regarding the likelihood of achieving appropriate 
therapeutic goals. Patient and parents’ values and preferences should be incorporated into shared 
decision making about treatment. Prolonged treatment with nucleoside or nucleotide analogs in 
children who are in the immune tolerant stage has not been shown to be associated with 
substantial benefit and carry risk for developing antiviral drug resistance, both to the agent 
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chosen, and related drugs.  An exception may be those immune tolerant children who will be 
undergoing immunosuppressive therapy, such as those who will be receiving chemotherapy, or 
stem cell or solid organ transplantation.  Patient selection and timing of treatment are critical 
decisions, in order to avoid overtreatment, maximize therapeutic benefit while limiting duration 
of therapy, and minimize risk for antiviral drug resistance later in life.  
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leTable 1: Characteristics of included studies:  






















Antiviral vs control trails: 
Bortolotti, 1998(17) Multicenter 
IFN-alpha 
(3–5 MU/m2 thrice weekly for 3-6 months) 





Control 117 5.5± 0.4 NR NR 
153.6± 
38.4 
Fujisawa, 2004(18) Japan 
IFN-alpha 
(0.1 MU/kg/day x 28 days) 




Vajro, 1996(19) Italy 
IFN-alpha 
(10 MU/ m2 body surface area intramuscularly, 
three times weekly, in the evening, for 1 year) 
13 6.9 ± 2.4 7.2 ± 7.1 238±197 48 HBeAg 
positive 
RCT 
Control 9 8.9 ± 3.1 7.2± 7 117± 67 48 
Barbera, 1994(20) Italy 
IFN-alpha 
(7.5 MU/ m2 three times weekly for 6 month) 




(3 MU/ m2 three times weekly for 6 month) 
19 8.1 ± 2.3 21%>6.7 72.4 ± 36 18 














Control 10 12(6-14) 
6.4 (5.7-6.6) 
 






(10 MU 3 times /week for 24 week 
subcutaneously) 
12 8.7 ± 4.2 
7.6 ± 7.7 
 
147 ± 72 18 
NR RCT IFN alpha 
(5 MU 3 times /week for 24 week subcutaneously) 
12 7.3 ± 2.5 
7.6 ± 7.6 
 
138 ± 90 18 
Control 12 8.5 ± 3.8 
7.5 ± 7.4 
  





(10 MU/ m2 body surface, intramuscularly, 3 




8.6 ± 8.5 
  




Control 12 8.3±1.8 
8.3 ± 8.1 
 





(3 MU/ m2 of body surface area 3 times/ week for 
1 week) 















Lai,1991(25) China IFN-alpha 29 6.5 (4-16) NR 12(5-34) 24 HBeAg RCT 
















le (5x106 u/m2 subcutaneously weekly for 16 weeks) positive 





(5 MU/ m2 for 5 consecutive days during the 
induction phase followed by 3 times/week for 11 











7.9 (6.7-9.04) 68 (35-266) 18 
Control 9 8.9 ± 3.1 7.2± 7 117± 67 48 
Jonas, 2002(27) Multinational 
Lamivudine 
(3 mg/kg once daily for 52 weeks) 
95 9(1-17) 

















Europe and the 
United State 
Tenofovir 
(300 mg once daily for 72 weeks) 
52 15.3± 1.34 7.3±  0.7 101 ±107.5 72 HBeAg–
positive 
RCT 
Placebo 54 15.3±1.43 7.5 ±0.7 101 ± 90 72 
Jonas, 2008(29) Multinational 
Adefovir dipivoxil 
(Depend on the age and weight, dose not to 
exceed 10 mg/day) 
115 10.8 ± 4.3 8.04 ± 0.2 111 ±81.6 6 HBeAg–
positive 
RCT 
Placebo 58 10.7 ± 3.9 7.9 ± 0.3 99±52.8 6 
Jonas, 2015(30) Multinational 
Entecavir 
Weight-based at 0.015 mg/kg oral solution (0.05 
mg/mL) once daily, up to a maximum of 0.5 
mg/day. 
120 10.5± 0.45 8.1 ± 0.1 107.1±5.4 24 HBeAg–
positive 
RCT 
Placebo 60 10.8± 0.62 7.9 ± 0.1 94.4 ±12.2 24 
 
  
















leTable 2: Risk of bias assessment for RCTs: 


















Risk of bias 
Antiviral vs control trails: 
VAJRO, 1996(19) NR NR NR Complete None None High 
Barbera, 1994(20) NR NR NR Complete None None High 
Utili, 1991(21) NR NR NR Complete None None High 
Ruiz-Moreno,1991(22) NR NR NR Complete None None High 
Ruiz-Moreno, 1990(23) NR NR NR Complete None None High 
Sokal, 1998(24) Random digit numbers NR NR Complete None None Moderate 
Lai, 1991(25) NR NR NR Complete None None High 
Gregorio, 1996(26) NR NR NR Complete None None High 
Jonas, 2002(27) Centrally randomized NR Double blinded Complete None None Low 
Murray, 2012(28) Centralized and stratified by age Unclear Unclear Complete None None Moderate 
Jonas, 2008(29) Centrally randomized NR Double blinded Complete None None Low 
Jonas, 2015 (30) Sponsor-designated center via 
an Interactive Voice Response 
System (IVRS) using a block 
size of 6 
NR Double blinded Complete None None Low 
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Figure 2: Forest plot of intermediate outcomes for antiviral therapy compared to control at post-treatment 
follow up < 12 months  
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Figure 3: Forest plot of intermediate outcomes for antiviral therapy compared to control at post-treatment 
follow up ≥ 12 months  
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Figure 4: Forest plot of intermediate outcomes for IFN-alpha compared to control at post-treatment follow 
up < 12 months  
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Figure 5: Forest plot of intermediate outcomes for IFN-alpha compared to control at post-treatment follow 
up ≥ 12 months  
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